logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Sodium-Glucose Cotransporter 2 Inhibitor class drugs

    FiltersReset Filters
    7 results

    • brenzavvy

      (Bexagliflozin)
      TheracosBio, LLC
      Usage: BRENZAVVY is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not recommended for patients with type 1 diabetes mellitus.

    • farxiga

      (DAPAGLIFLOZIN)
      AstraZeneca Pharmaceuticals LP
      Usage: FARXIGA (dapagliflozin) is indicated for reducing risks associated with chronic kidney disease, heart failure, and for improving glycemic control in adults and pediatric patients (10 years and older) with type 2 diabetes mellitus, alongside diet and exercise. It is not recommended for type 1 diabetes or specific kidney conditions.

    • glyxambi

      (empagliflozin and linagliptin)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: GLYXAMBI, a combination of empagliflozin and linagliptin, is indicated to improve glycemic control in adults with type 2 diabetes mellitus alongside diet and exercise. Empagliflozin also reduces cardiovascular death risk in patients with type 2 diabetes and existing cardiovascular disease. It is not suitable for type 1 diabetes or certain conditions.

    • inpefa

      (sotagliflozin)
      Lexicon Pharmaceuticals, Inc.
      Usage: INPEFA is indicated for reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

    • jardiance

      (Empagliflozin)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: JARDIANCE is indicated for reducing the risk of cardiovascular death and hospitalization in adults with heart failure, chronic kidney disease, and type 2 diabetes with established cardiovascular disease. It also aids glycemic control as an adjunct to diet and exercise in patients aged 10 and older with type 2 diabetes.

    • synjardy

      (empagliflozin and metformin hydrochloride)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: SYNJARDY and SYNJARDY XR are indicated as adjuncts to diet and exercise to improve glycemic control in adults and pediatric patients (≥10 years) with type 2 diabetes mellitus. Empagliflozin also reduces the risk of cardiovascular death and heart failure hospitalization in adults with established cardiovascular disease.

    • trijardy xr

      (empagliflozin, linagliptin, metformin hydrochloride)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: TRIJARDY XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Additionally, empagliflozin, one of its components, helps reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.